Role SGLT2 inhibitor therapy in patients with transthyretin cardiac amyloidosis: a GRADE assessed systematic review and meta-analysis
SGLT2 inhibitors, when used alongside disease-modifying agents, appear to improve survival and renal outcomes in patients with ATTR-CM. However, these findings are derived from observational studies with their inherent biases and must be interpreted with caution. High-quality randomised controlled trials are needed to confirm these associations and better define their clinical role in ATTR-CM.
Authors
- Fatima Wahid
- Ayesha Afridi (ORCID: https://orcid.org/0000-0002-8012-0613)
- M. Nawaz
- Ahmed Ali Khan (ORCID: https://orcid.org/0000-0002-2747-8739)
- Salman Tariq (ORCID: https://orcid.org/0000-0002-9935-4516)
- Muhammad Shaheer Bin Faheem (ORCID: https://orcid.org/0009-0005-6878-2031)
- Hamed Habib
- Kalsoom Zulfiqar
- Muhammad Humayoon
Institutions
- University of Sargodha (PK)
- Frontier Medical College (PK)
- Karachi Institute of Heart Diseases (PK)
- Foundation University Medical College (PK)
- Aga Khan University Hospital (PK)
- GIFT University (PK)
- Pakistan Institute of Medical Sciences (PK)
- Ziauddin University (PK)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1080/00015385.2025.2594908
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.61